LL-37

What Is LL-37?

LL-37 is the only cathelicidin antimicrobial peptide expressed in humans. It is a 37-amino acid, amphipathic, alpha-helical peptide derived from the C-terminal cleavage of its precursor protein hCAP-18 (human cationic antimicrobial protein 18 kDa). The name “LL-37” simply describes its length (37 residues) and its first two amino acids (Leu-Leu).

LL-37 is a fundamental component of the human innate immune system. It is produced by neutrophils, monocytes, NK cells, T cells, B cells, and epithelial cells throughout the body — skin, respiratory tract, gastrointestinal tract, and urogenital tract. It serves as a first-line defense against invading microorganisms and plays complex roles in inflammation, wound healing, and immune regulation.

The grey market has repackaged this endogenous immune peptide as an injectable therapeutic, primarily marketed for immune support, infection resistance, and Lyme disease treatment. While LL-37’s biology is well-characterized, its use as an exogenous therapeutic is entirely unvalidated. No clinical trial of injected LL-37 has been completed in humans.

How It Works

LL-37 is a genuinely multifunctional molecule with well-characterized mechanisms:

Direct antimicrobial activity: LL-37 is a cationic (positively charged) peptide that electrostatically binds to the negatively charged membranes of bacteria, fungi, and enveloped viruses. At sufficient concentrations, it disrupts membrane integrity, killing the pathogen. It demonstrates broad-spectrum activity against both Gram-positive and Gram-negative bacteria, including antibiotic-resistant strains.

Anti-biofilm activity: At concentrations below those needed to kill bacteria directly (sub-MIC), LL-37 can inhibit biofilm formation and disrupt established biofilms. This is particularly relevant for chronic infections where biofilm-protected bacteria are resistant to conventional antibiotics.

LPS neutralization: LL-37 binds and neutralizes bacterial lipopolysaccharide (LPS/endotoxin), preventing the inflammatory cascade that leads to septic shock. This “endotoxin-neutralizing” property is well-documented in animal models.

Immunomodulation: This is where LL-37’s biology gets complex. It simultaneously:

• Suppresses pro-inflammatory cytokine release from stimulated neutrophils (anti-inflammatory)
• Recruits immune cells (chemotaxis) to infection sites (pro-inflammatory/pro-defense)
• Stimulates NET (neutrophil extracellular trap) release for bacterial trapping
• Promotes angiogenesis and tissue regeneration (wound healing)
• Activates dendritic cells and bridges innate and adaptive immunity

Vitamin D connection: LL-37 production is upregulated by vitamin D3. This is one mechanism by which vitamin D deficiency impairs immune function — low vitamin D means low cathelicidin, means reduced first-line antimicrobial defense.

What the Research Actually Shows

Basic Science and Animal Data

The basic science of LL-37 is extensive — hundreds of published papers characterize its antimicrobial, anti-biofilm, immunomodulatory, and wound-healing properties. This is some of the strongest mechanistic evidence for any peptide in our database. The critical issue is translation to exogenous therapeutic use.

Bucki R et al. (Arch Immunol Ther Exp, 2010;58(1):15–25): Comprehensive review establishing LL-37 as a “multitask” antimicrobial peptide with direct killing activity, LPS neutralization, immune cell recruitment, and wound healing promotion.

Alalwani SM et al. (Eur J Immunol, 2010;40(4):1118–1126): Demonstrated the elegant dual mechanism — LL-37 simultaneously reduced inflammatory cytokine release from neutrophils (dampening harmful inflammation) while enhancing their bacterial killing capacity (improving defense). CRAMP-knockout mice (lacking the mouse equivalent of LL-37) showed impaired neutrophil antimicrobial function.

Overhage J et al. (Infect Immun, 2008;76(9):4176–4182): At sub-MIC concentrations, LL-37 inhibited Pseudomonas aeruginosa biofilm formation and could disrupt preformed biofilms.

Sepsis models: In cecal ligation and puncture (CLP) models, LL-37 improved survival through at least three mechanisms — suppressing macrophage pyroptosis, enhancing antimicrobial NET release, and stimulating neutrophil ectosome production.

The Autoimmunity Complication

LL-37 has a darker side that grey-market vendors rarely mention:

Kahlenberg JM & Kaplan MJ (J Immunol, 2013;191(10):4895–4901): LL-37 is implicated in the pathogenesis of several autoimmune conditions. In psoriasis, LL-37 forms complexes with self-DNA that activate plasmacytoid dendritic cells, triggering the type I interferon response that drives psoriatic inflammation. LL-37-DNA complexes have also been identified in lupus pathogenesis. In atherosclerosis, LL-37 promotes macrophage foam cell formation and vascular inflammation.

This is not a minor caveat. LL-37 can be both protective (against infection) and pathogenic (in autoimmune contexts). Injecting supraphysiological doses of a peptide with documented roles in autoimmune disease initiation is not a trivial decision.

What’s Missing

• No completed clinical trial of injected LL-37 in humans
• No established therapeutic dose for exogenous administration
• No pharmacokinetic data for subcutaneous injection — LL-37 has a short half-life and is rapidly degraded by proteases in biological fluids
• Autoimmune risk from supraphysiological LL-37 exposure is biologically plausible and documented in mechanistic studies but has not been assessed in an interventional context
• Cytotoxicity at high concentrations — LL-37 can damage host cells at elevated levels, creating a narrow therapeutic window
• Manufacturing cost — LL-37 is a 37-residue peptide that is expensive to synthesize at pharmaceutical purity. Grey-market products at low prices raise quality concerns

Safety Profile

No human interventional safety data exists. The concerns are theoretical but grounded in published biology:

Autoimmune activation: LL-37’s role in psoriasis and lupus pathogenesis is well-documented. Individuals with autoimmune predisposition may face elevated risk from exogenous LL-37 administration.

Cytotoxicity: At concentrations exceeding the antimicrobial range, LL-37 can damage host cell membranes — it is, after all, a membrane-disrupting peptide. The line between antimicrobial efficacy and host cell toxicity is narrow.

Proteolytic instability: LL-37 is rapidly degraded by serine proteases, matrix metalloproteinases, and other enzymes present in blood and tissue. Whether subcutaneously injected LL-37 achieves meaningful systemic concentrations is unknown.

Immunomodulation at supraphysiological doses: LL-37 activates multiple immune pathways simultaneously. The net effect of supraphysiological administration — anti-inflammatory, pro-inflammatory, or immunodysregulatory — is unpredictable without clinical data.

Legal and Regulatory Status

FDA: Category 2 — LL-37 cannot be legally compounded by 503A or 503B pharmacies. Not approved for any indication.

WADA: Not explicitly named on the 2026 Prohibited List but would likely fall under S0 (Non-Approved Substances) as an unapproved pharmacological agent.

Clinical development status: Several LL-37 derivatives and analogues are in early clinical development for topical wound healing applications. The original LL-37 peptide itself has not advanced through clinical trials for systemic use, largely due to proteolytic instability, cytotoxicity concerns, and manufacturing costs.

Common Vendor Claims vs. Reality

What vendors say	What the evidence shows
”Natural antibiotic — your body’s own defense”	LL-37 is an endogenous antimicrobial peptide. Injecting synthetic LL-37 is not the same as natural immune function
”Treats Lyme disease”	No clinical evidence. LL-37 has in vitro activity against Borrelia species, but this does not constitute Lyme disease treatment
”Boosts immune system”	LL-37 modulates immunity in complex ways — it can both enhance antimicrobial defense and trigger autoimmune pathology
”Safe because it’s natural”	LL-37 is implicated in psoriasis and lupus pathogenesis. “Natural” does not equal “safe at supraphysiological doses"
"Anti-biofilm therapy”	In vitro anti-biofilm activity is documented. Whether injected LL-37 reaches biofilm sites at effective concentrations in vivo is unknown
”Clinically proven”	False — no clinical trial of injected LL-37 has been completed

The Bottom Line

LL-37 presents a paradox. Its basic science is among the most thoroughly characterized of any peptide in our database — the immunological mechanisms are well-established across hundreds of papers. And yet this wealth of mechanistic knowledge has not been translated into a single completed clinical trial for exogenous injection.

The reason is not lack of interest but practical barriers: rapid proteolytic degradation, cytotoxicity at high concentrations, manufacturing costs, and — importantly — the autoimmune activation concern. The pharmaceutical industry has responded by developing LL-37 analogues with improved stability and selectivity rather than attempting to use the native peptide therapeutically. Omiganan, lytixar, and other cathelicidin-derived compounds are in clinical development specifically because LL-37 itself has too many limitations for direct therapeutic use.

Grey-market vendors have bypassed these well-documented limitations by selling injectable LL-37 without addressing whether it survives in vivo, reaches target tissues, or avoids autoimmune activation at the doses used. This is not a knowledge gap that can be bridged by consumer enthusiasm.

---

This profile will be updated as new research becomes available. Last reviewed: March 2, 2026.